Long-term Persistence of Oral Human Papillomavirus Type 16: The HPV Infection in Men (HIM) Study

Christine M. Pierce Campbell1,2, Aimée R. Kreimer3, Hui-Yi Lin4, William Fulp4, Michael T. O’Keefe1, Donna J. Inglese1,2, Martha Abrahamsen1,2, Luisa L. Villa5,6,7, Eduardo Lazcano-Ponce8, and Anna R. Giuliano1,2

Abstract
Persistent infection with oral HPV16 is believed to drive the development of most oropharyngeal cancers. However, patterns of oral HPV16 persistence remain understudied, particularly among HIV-negative individuals. Oral HPV16 persistence was evaluated among 1,626 participants of the HPV Infection in Men (HIM) Study. Twenty-three oral HPV16-positive men who provided an oral gargle sample on ≥2 study visits were included in the analysis. Archived oral samples from all follow-up visits were tested for HPV16 using Linear Array and INNO-LiPA detection methods. Persistence was evaluated using consecutive HPV16-positive visits held approximately 6 months apart and using the Kaplan–Meier method. Oral HPV16-positive men were aged 18 to 64 years [median, 36 years; interquartile range (IQR), 25–42] and were followed for a median of 44.4 months (IQR, 29.9–49.5). Of 13 incident infections, 4 (30.8%) persisted ≥12 months, 1 (10.0%) persisted ≥24 months, and none persisted ≥36 months [median infection duration, 7.3 months; 95% confidence interval (CI), 6.4–NA]. Of 10 prevalent infections, 9 (90.0%) persisted ≥12 months, 8 (80.0%) persisted ≥24 months, 4 (57.1%) persisted ≥36 months, and 2 (40.0%) persisted ≥48 months (median infection duration, NA). Twelve-month persistence of incident infections increased significantly with age (Ptrend = 0.028). Prevalent oral HPV16 infections in men persisted longer than newly acquired infections, and persistence appeared to increase with age. These findings may explain the high prevalence of oral HPV observed at older ages. Understanding oral HPV16 persistence will aid in the identification of men at high-risk of developing HPV-related oropharyngeal cancer. Cancer Prev Res; 1:7. ©2014 AACR.

Introduction
Mounting evidence in some economically developed countries suggests that human papillomaviruses (HPV) cause the majority of oropharyngeal cancers among men (1, 2), with HPV type 16 implicated in most cases (3). In the United States, oropharyngeal cancers incidence is 4-fold higher among men than women (4).

Though still considered a rare cancer (<10 per 100,000 individuals; ref. 4), HPV-positive oropharyngeal cancer incidence has increased significantly in recent decades among men (1, 4), with the annual number of overall oropharyngeal cancer cases now surpassing that of cervical cancers (4).

Most HPV-driven oropharyngeal cancer cases are diagnosed at an advanced clinical stage (III–IV; ref. 5), and treatment often causes substantial morbidity, including facial disfigurement and permanent difficulties in speaking, swallowing, and breathing. Unfortunately, there are no clinically validated screening tests available to detect oropharyngeal cancers at an earlier stage or to predict the risk of developing HPV-driven oropharyngeal cancers. Though primary prevention of oral HPV through prophylactic vaccination is promising (6), there is no definitive evidence that HPV vaccines will prevent new oral HPV infection and subsequent disease. Furthermore, generations of men and women will remain unprotected, including individuals currently outside of the recommended age range for vaccination and those already infected with oral HPV (7), emphasizing the need for the development of oral HPV prevention and early oropharyngeal cancer detection methods, particularly among high-risk individuals.

Advancing our knowledge of the natural history of genital HPV infection has led to important innovations in the prevention of cervical cancer (e.g., cervical HPV testing and prophylactic HPV vaccination). Similar data on oral HPV natural history are needed to advance the development of oropharyngeal cancer interventions. Unfortunately, oral HPV natural history are needed to advance the development of oropharyngeal cancer interventions. Unfortunately, oral HPV natural...
history remains understudied. Like cancers at other anatomic sites, persistent oral HPV infection may be the driving factor in oropharyngeal cancer carcinogenesis; therefore, it is crucial to examine each step along the continuum of carcinogenesis, from initial HPV infection to development of cancer. Previously, we described the prevalence (8) and acquisition (9) of oral HPV detected among otherwise healthy men enrolled in a large HPV natural history study. Here, we supplement these data with an evaluation of long-term oral HPV16 persistence among the same cohort of men.

Materials and Methods

Study population

The HPV Infection in Men (HIM) Study is an ongoing, multinational cohort study of the natural history of genital HPV infections (10, 11). More than 4,000 men ages 18 to 70 years were recruited from a variety of population sources within Brazil, Mexico, and the United States beginning in 2005. Men reported no previous diagnosis of anogenital cancers, had never been diagnosed with anogenital warts, and reported no symptoms of or treatment for a sexually transmitted infection, including HIV/AIDS to be eligible for the study. In 2007, oral sample collection was initiated, and details of the HIM Study oral HPV substudy can be found elsewhere (8, 9). Briefly, the first consecutively recruited 1,626 men who provided oral gargle samples on ≥2 study visits were tested for oral HPV, none of whom reported a history of head and neck cancer (9). Twenty-eight men were positive for oral HPV16 and 23 men had sufficient data to evaluate oral HPV16 persistence (i.e., ≥6 months of follow-up after the initial infection).

The Human Subjects Committees of the University of South Florida (Tampa, FL), Ludwig Institute for Cancer Research (São Paulo, Brazil), Centro de Referência e Treinamento em Doenças Sexualmente Transmissíveis e AIDS (São Paulo, Brazil), and Instituto Nacional de Salud Pública de México (Cuernavaca, Mexico) approved all study procedures, and all participants provided written informed consent.

Procedures

Participants attended a pre-enrollment (baseline) visit, an enrollment visit (2 weeks postbaseline), and follow-up visits every 6 months for up to 4 years. At each visit, participants completed a computer-assisted self-interview with questions about sociodemographic characteristics and potential risk factors, and underwent a clinical examination in which genital and oral samples were collected. Each participant was asked to rinse with and gargle 15 mL of locally available mouthwash for a total of 30 seconds (8). The sample was centrifuged at 3,000 × g for 15 minutes at 4 °C, the supernatant was decanted, and the cell pellet was resuspended in 20 mL of sterile saline. To ensure even sample distribution, centrifugation was repeated, and the cell pellet was resuspended in 1.2 mL of saline with repeated pipetting and vortexing. Samples were then stored at −80°C for PCR and genotyping analyses.

HPV DNA extraction and genotyping have been described previously (8, 9). Briefly, oral cells underwent robotic DNA extraction using the QIAamp Media MDx Kit (Qiagen) in accordance with the manufacturer’s instructions. Samples were tested for the presence of HPV DNA with PGMY09/11 PCR, and HPV genotyping was conducted with Linear Array (Roche Molecular Diagnostics), irrespective of HPV PCR results. The Linear Array assay detects 37 mucosal HPV types, classified as high-risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) or low-risk [6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 66, 67, 70, 71, 72, 73, 81, 82, 82 subtype IS39, 83, 84, and 89 (CP6108; ref. 12]. To evaluate long-term infection persistence among oral HPV16-positive study participants, we identified and retrieved all available oral gargle samples that were archived through the end of the study. Men HPV genotyping of all archived samples from these men was conducted using Linear Array. For 11 men, at least one intervening negative result occurred among a series of positive results, suggesting that oral HPV16 viral load fell below the lower limit of detection of the assay. We used a more sensitive assay, INNO-LiPA HPV Genotyping Extra (Fujirebio, Ghent, Belgium), to confirm the results of 14 specimens that, according to Linear Array, were intervening negatives (single or multiple negatives) between positive visits. Eleven specimens (78.6%) tested HPV16-positive using INNO-LiPA, although three specimens remained HPV16-negative using INNO-LiPA. If a visit tested HPV16-positive by INNO-LiPA, that visit was considered HPV16-positive, overriding the results of the Linear Array assay. If an intervening negative test HPV16-negative by both Linear Array and INNO-LiPA, but had prior and subsequent HPV16-positive visits, the intervening negative visit was considered a false negative; this occurred for three men (two with prevalent HPV and one with incident HPV). We also used INNO-LiPA to test a random sample of five HPV16-positive and five HPV16-negative specimens previously determined using Linear Array; all (100%) of the HPV16-positive specimens remained positive and all (100%) of the HPV16-negative specimens remained negative. Using results from both assays, we evaluated oral HPV16 persistence and clearance for up to 56.4 months of follow-up.

Statistical analysis

Persistence was first evaluated using a definition based on consecutive oral HPV16-positive visits. Persistence was estimated at 6-month intervals, as study visits occurred approximately 6 months apart; however, as pre-enrollment and enrollment visits occurred 2 weeks apart, oral HPV16 results from these visits were combined into one visit (i.e., the combined visit was considered positive if either visit was positive). Six-month type-specific persistence was defined as the presence of oral HPV16 DNA on two or more consecutive study visits, 12-month type-specific persistence as the presence of oral HPV16 DNA on three or more consecutive study visits, and so on. If a single HPV-negative visit occurred between two HPV-positive visits, that visit was deemed a false negative and was treated as though it were an HPV-positive visit. Persistence was reported as a proportion and was calculated as the number of persistent HPV16 infections divided by the total number of HPV16 infections detected among men who had been followed for that period of time or longer. As not all men were followed for 48 months, the total number of infections (i.e., denominator) changed over time.

Persistence was also evaluated using the Kaplan–Meier method to estimate the cumulative probability of infection throughout the entire study period and median time to clearance. Infection clearance was defined as two or more HPV16-negative visits following an HPV16-positive visit. However, an infection was considered cleared if a single HPV-negative occurred at the final study visit, as there was insufficient evidence to consider
Long-term Oral HPV16 Persistence in Men

though not statistically significant, 12-month persistence of prevalent infections also increased with age ($P_{\text{trend}} = 0.604$). No statistically significant age trends were observed in the persistence of incident or prevalent infections at 24, 36, or 48 months (data not shown). Furthermore, no associations were observed between oral HPV16 persistence at 12, 24, 36, or 48 months and cigarette smoking, alcohol intake, country, educational attainment, marital status, sexual orientation, lifetime numbers of sexual partners, or ever/recent oral sexual behaviors (data not shown). In analyses using Cox regression, oral HPV16 persistence was not associated with any sociodemographic or behavioral characteristic, including age (data not shown).

Discussion

In this study, we describe patterns of long-term oral HPV16 persistence among otherwise healthy men. Using two sensitive HPV genotyping assays and analyzing additional specimens from a longer follow-up period allowed us to more accurately estimate long-term persistence compared with our previous studies (9). Our results indicate that prevalent HPV16 infections of the oral cavity are more likely to persist than newly acquired infections, and persistence appears to increase with age among men.

Few studies conducted to date have evaluated oral HPV16 persistence, none of which have reported data separately for prevalent and incident infections over such a long time span and across such a broad age range among otherwise healthy individuals. Furthermore, persistence estimates have varied widely, likely due to differences in definitions of persistence, study populations, study visit intervals, length of follow-up, oral sampling techniques, and HPV DNA detection methods. In a recent study by Mooij and colleagues conducted among 413 HIV-negative men who have sex with men (MSM), 3 of 9 (33%) prevalent oral HPV16 infections persisted 6 months (13). In a small study of 59 HIV-negative women, D’Souza and colleagues determined that three of five (60%) prevalent oral HPV infections persisted 6 months (14); however, the authors did not provide separate estimates for oral HPV16. As part of the large, prospective Finnish Family HPV (FFHPV) Study, an analysis of oral HPV among 121 male and 216 female spouses observed that 11 of 20 (55%) prevalent high-risk oral HPV infections detected at baseline persisted two years among men, and 15 of 31 (50%) persisted 2 years among women (15); however, these estimates were likely overestimated, as persistence analyses were not genotype-specific and relied only on prevalently detected infections. In subsequent FFHPV Study analyses, HPV16 was identified as the most frequent type to persist at the oral cavity, with longer persistence observed among men (mean, 22 months; ref. 16) than among women (mean, 19 months; ref. 17), although these analyses combined prevalent and incident HPV infections. In our study of 1,626 healthy, adult men, we report higher rates of persistence, with 100% of prevalent oral HPV16 infections persisting ≥6 months and 80% persisting ≥2 years, and 39% of incident infections persisting ≥6 months and 10% persisting ≥2 years.

Existing oral HPV16 infections (i.e., prevalent infections detected at baseline) were more likely to persist than newly acquired infections (i.e., incident infections detected at a follow-up visit), as predicted. Prevalent HPV infections are
Recent studies have sought to understand rates and determinants of oral HPV acquisition and clearance and, in doing so, have raised important questions about the effects of gender and age. In a large, population-based study of oral HPV prevalence (19), men were three times more likely than women to have a prevalent infection, mirroring the gender ratio observed in HPV-positive oropharyngeal cancers. In the same study, a significant bimodal age distribution was observed among men, with the peak prevalence occurring among men over 50 years, which is contrary to the established decline in cervical HPV prevalence with age (20). In a previous analysis conducted among men in the HIM Study (9), we showed that the risk of acquiring a new oral HPV infection remained constant across the lifespan, suggesting that the peak in prevalence at older ages is likely due to an increase in infection persistence. Here, we suggest that persistence of incident oral HPV16 infections increases with age among men, a finding consistent with one study conducted among women (14). Altogether, these data support the hypothesis that increased prevalence of oral HPV16 detected among men at older ages is likely due to increased duration of infections and not increased acquisition, a pattern consistent with that of cervical HPV infection persistence (18).

Table 1. Characteristics of men with oral HPV16 at the time of enrollment into the oral HPV substudy (Cont’d)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Total (n=23)</th>
<th>Prevalent (n=10)</th>
<th>Incident (n=13)</th>
<th>( P^a )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time since last oral sex (days)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( \geq 25 )</td>
<td>4 (17.4%)</td>
<td>1 (4.3%)</td>
<td>1 (7.7%)</td>
<td></td>
</tr>
<tr>
<td>Missing data</td>
<td>6 (26.1%)</td>
<td>3 (30.0%)</td>
<td>3 (23.1%)</td>
<td></td>
</tr>
<tr>
<td>( &gt;3-10 )</td>
<td>2 (8.7%)</td>
<td>0 (0%)</td>
<td>2 (15.4%)</td>
<td></td>
</tr>
<tr>
<td>( &gt;10-30 )</td>
<td>3 (13.0%)</td>
<td>2 (20.0%)</td>
<td>1 (7.7%)</td>
<td></td>
</tr>
<tr>
<td>( &gt;30 )</td>
<td>6 (26.1%)</td>
<td>2 (20.0%)</td>
<td>4 (30.8%)</td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>4 (17.4%)</td>
<td>3 (30.0%)</td>
<td>1 (7.7%)</td>
<td></td>
</tr>
<tr>
<td>Missing data</td>
<td>2 (8.7%)</td>
<td>0 (0%)</td>
<td>2 (15.4%)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: MSW, men who have sex with women; MSM, men who have sex with men; MSWM, men who have sex with women and men.

\(^{a}\)Exact Pearson \( \chi^2 \) \( P \) value using Monte Carlo estimation.

\(^{b}\)Question not asked among all men because the study questionnaire was revised in 2007 after oral sample collection began.
regardless of epithelial site of infection. Larger cohort studies are needed to elucidate the biologic and behavioral mechanisms underlying oral HPV persistence.

The role of tobacco use in oral HPV natural history remains unclear. In our previous analysis, cigarette smokers were significantly more likely to acquire a new oral high-risk HPV infection (9); however, here we report no association between smoking and oral HPV16 persistence. This finding is contrary to two other studies that demonstrated that any (14) and high-risk (16) oral HPV were more likely to persist among current smokers. Smoking is known to cause local inflammation and immunosuppression (27) and is thought to increase susceptibility to a new HPV infection at the oral epithelium. However, smoking has also been found to induce expression of secretory leukocyte protease inhibitor (SLPI; ref. 28), an innate immunity-associated protein that has been hypothesized to protect against HPV infection (29). Future studies are needed to understand the complex role of smoking and SLPI with respect to oral HPV natural history before definitive interpretations are made.

This is one of the first studies to provide detailed estimates of long-term oral HPV16 persistence using data from a large cohort of healthy, adult men. These findings are more likely to represent oral HPV16 natural history than previous reports, due to increased sensitivity of HPV DNA detection and longer follow-up of study participants. However, the following limitations should be considered. First, despite having such a large cohort, we acknowledge that oral HPV16 infection is rare among otherwise healthy men, thus limiting our ability to identify factors significantly associated with infection persistence. However, to our knowledge, the HIM Study is the only existing HPV natural history study with the ability to describe long-term oral HPV persistence in healthy men. Second, our definition of persistence was based on consecutive study visits and assumed that men returned every 6 months, on schedule. While most men adhered to this protocol, some may have returned for the next visit later than scheduled, increasing the time between visits. As a result, we performed an additional time-to-event analysis based on the Kaplan–Meier method. Third, we may have underestimated persistence among one individual who had a single HPV16-negative result at his final study visit. This individual’s infection was considered cleared in our analysis, although it is possible that this specimen contained a low viral load that was undetectable by Linear Array. Finally, intermittent negativity was observed among some HPV16-positive men, which has been described in other studies (30). These negative visits may indicate a low copy number infection that fell below the lower limit of assay detection (31); however, we acknowledge that this pattern may also represent reactivation of a latent infection or reinfection after a previously cleared infection. In the current study, we utilized a more sensitive assay, INNO-LiPA, to re-test samples that appeared to have fallen below the lower limit of detection, and indeed found that we would have misclassified several specimens as negative and therefore underestimated our estimates of infection persistence, had we relied on the linear array method alone.

Understanding patterns of oral HPV persistence is essential in the development of HPV-driven oropharyngeal cancers prevention and early detection strategies. Long-term persistence of high-risk genital HPV infection is the strongest predictor of cervical precancer and cancer development in women (32). Among all high-risk types, HPV16 has been shown to persist longest and confer the highest risk of developing precancerous lesions. More than 40% of women with cervical HPV16 infections persisting at least one year develop cervical intraepithelial neoplasia grade 2 or more severe lesions within 3 years (33). Given that the overwhelming majority of prevalent oral HPV16 infections detected here persisted beyond one year, and 40% persisted beyond 4 years, there is a clear need to evaluate whether long-term persistent oral HPV16 infection can predict future oropharyngeal cancer risk. With a constant rate of acquisition of new oral HPV infections (9) and higher likelihood of persistence with age, mid-adult and older men appear to be at the highest risk of oral HPV infection and should be the focus of prevention interventions.

Table 2. Long-term persistence of prevalent and incident oral HPV16 infections in men (n = 23)

<table>
<thead>
<tr>
<th>Persistence</th>
<th>Prevalent (n = 10)</th>
<th>Incident (n = 13)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number of persistent infections/number of total infections</td>
<td>%</td>
</tr>
<tr>
<td>≥6 months</td>
<td>10/10</td>
<td>100</td>
</tr>
<tr>
<td>≥12 months</td>
<td>9/10</td>
<td>90.0</td>
</tr>
<tr>
<td>≥18 months</td>
<td>9/10</td>
<td>90.0</td>
</tr>
<tr>
<td>≥24 months</td>
<td>8/10</td>
<td>80.0</td>
</tr>
<tr>
<td>≥30 months</td>
<td>6/8</td>
<td>75.0</td>
</tr>
<tr>
<td>≥36 months</td>
<td>4/7</td>
<td>57.1</td>
</tr>
<tr>
<td>≥42 months</td>
<td>3/6</td>
<td>50.0</td>
</tr>
<tr>
<td>≥48 months</td>
<td>2/5</td>
<td>40.0</td>
</tr>
</tbody>
</table>

*As not all men were followed for 48 months, the number of total infections changes over time.

Figure 1. Kaplan–Meier estimates of prevalent and incident oral HPV16 persistence in men (n = 23).
Disclosure of Potential Conflicts of Interest

L.L. Villa has received speakers’ bureau honoraria from Merck Sharp & Dohme and is a consultant/advisory board member for Merck Sharp & Dohme and BD Technologies. No potential conflicts of interest were disclosed by the other authors.

Disclaimer

The contents of the report do not necessarily represent the official views of the NCI or the NIH, and the opinions expressed are those of the authors and do not necessarily represent those of Merck Sharp & Dohme.

Authors’ Contributions

Conception and design: C.M. Pierce Campbell, A.R. Kreimer, H.-Y. Lin, L.L. Villa, A.R. Giuliano

Development of methodology: C.M. Pierce Campbell, A.R. Kreimer, M. O’Keefe, D. Ingles

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): A.R. Kreimer, M. O’Keefe, D. Ingles, M.E. Abrahamsen, L.L. Villa, E. Lazcano-Ponce, A.R. Giuliano

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): C.M. Pierce Campbell, H.-Y. Lin, W.J. Fulp, D. Ingles, E. Lazcano-Ponce

Writing, review, and/or revision of the manuscript: C.M. Pierce Campbell, A.R. Kreimer, W.J. Fulp, M. O’Keefe, D. Ingles, M.E. Abrahamsen, L.L. Villa, E. Lazcano-Ponce, A.R. Giuliano

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): W.J. Fulp, M. O’Keefe

Study supervision: C.M. Pierce Campbell, H.-Y. Lin, M.E. Abrahamsen, L.L. Villa, A.R. Giuliano

Acknowledgments

The authors thank the HIM Study participants and teams in the United States (H. Moffitt Cancer Center, Tampa, FL; J.L. Messina, C. Gage, K. Eyring, K. Kennedy, K. Isaacs, A. Bobanic, B.A. Sirak, M.R. Papenfuss), Brazil (Centro de Referencia e Treinamento em DST/AIDS, Fundação Faculdade de Medicina Instituto do Cancer do Estado de São Paulo, and Ludwig Institute for Cancer Research, São Paulo; M.L. Baggio, L. Galan, R.J. Carvalho da Silva, L. Sichero, E. Gomes, E. Brito, F. Cernichiaro, R. Cintra, R. Cunha, R. Matsuo, V. Souza, B. Fietzek, R. Hessel, V. Relvas, F. Silva, J. Antunes, G. Ribeiro, R. Bocalon, R. Otero, R. Terreri, S. Araujo, M. Ishibashi, CRT-DST/AIDS nursing team), and Mexico (Instituto Mexicano del Seguro Social and Instituto Nacional de Salud Pública, Cuernavaca; J. Salmerón, M. Quiterio Trenado, A. Cruz Valdez, R. Alvear Vásquez, O. Rojas Juárez, R. González Sosa, A. Salgado Morales, A. Rodríguez Galván, P. Román Rodríguez, A. Landa Vélez, M. Zepeda Mendoza, G. Díaz García, V. Chávez Abarca, J. Ruiz Soteló, A. Gutiérrez Luna, M. Hernández Nevárez, G. Sánchez Martínez, A. Ortiz Rojas, C. Barrera Flores). The authors also received valuable assistance from the Biostatistics Core and Tissue Core Facilities at the H. Lee Moffitt Cancer Center and Research Institute, an NCI designated Comprehensive Cancer Center, supported under NIH grant P30 CA076922.

Grant Support

The infrastructure of the HIM Study cohort was supported through a grant from the NCI, NIH (R01 CA098803; to A. Giuliano). Funding for a subset of oral sample collection and HPV testing was provided by the NCI Intramural Program to A. Kreimer. Additional funding for testing of the remaining oral samples was provided through a research grant from the Investigator-Initiated Studies Program of Merck Sharp & Dohme (to A. Giuliano). C.M. Pierce Campbell was supported, in part, by a Postdoctoral Fellowship (PF-13-222-01-MPC) from the American Cancer Society.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received September 8, 2014; revised October 28, 2014; accepted November 13, 2014; published OnlineFirst January 9, 2015.

References


Cancer Prevention Research

Long-term Persistence of Oral Human Papillomavirus Type 16: The HPV Infection in Men (HIM) Study


Cancer Prev Res  Published OnlineFirst January 9, 2015.

Updated version  Access the most recent version of this article at:
doi:10.1158/1940-6207.CAPR-14-0296

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.